- Loblaw’s adjusted Earnings Per Share (EPS) for Q2 is C$2.15, higher than last year’s C$1.94 and slightly above the estimate of C$2.14.
- Food retail comparable sales increased by 0.2%, compared to a 6.1% increase in the same period last year.
- Drug retail comparable sales rose by 1.5%, whereas last year they were up by 5.7%.
- Total revenue for Loblaw reached C$13.95 billion, a 1.5% increase from last year, but below the estimated C$14.17 billion.
- Current analyst recommendations include 6 buys, 3 holds, and 2 sells.
A look at Loblaw Cos Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts indicate a promising long-term outlook for Loblaw Companies Limited, a Canadian retail and wholesale food distributor. According to Smartkarma Smart Scores, the company performs well in terms of Growth and Momentum, both scoring a solid 4 out of 5. This suggests a positive trajectory for Loblaw Cos in terms of expanding its operations and maintaining market momentum over the long run.
While Loblaw Cos scored lower in Value, Dividend, and Resilience, with scores of 2 for each category, the overall picture points towards a company with potential for growth and a strong market presence. With a commitment to navigating changing market dynamics, Loblaw Cos’ diverse operations across Canada position it to adapt to evolving consumer preferences and industry trends.
**Summary:** Loblaw Companies Limited is a retail and wholesale food distributor with operations spanning across Canada, operating company and franchisee stores, warehouses, and cash and carry outlets.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
